Histone H3.3 chaperone complex (H3.3 chaperone complex)

Histone H3.3 chaperone complexes are specialized protein assemblies, primarily the HIRA and DAXX/ATRX complexes, that mediate the replication-independent deposition of the histone variant H3.3 into the genome (Lewis et al., 2010; Goldberg et al., 2010). The HIRA complex, consisting of HIRA, UBN1, and CABIN1, is responsible for incorporating H3.3 into euchromatic regions such as active promoters, enhancers, and gene bodies, thereby facilitating gene expression and DNA repair (Tagami et al., 2004; Ray-Gallet et al., 2002). Conversely, the DAXX/ATRX complex targets H3.3 to heterochromatic regions, including telomeres and pericentric repeats, which is essential for maintaining chromatin silencing and genomic stability (Drane et al., 2010; Wong et al., 2010). These complexes are critical for cellular processes such as development, differentiation, and senescence, and their dysregulation is linked to various pathologies (Rai et al., 2011; Wasylishen et al., 2020). Mutations in ATRX and DAXX are frequently observed in cancers like pediatric glioblastoma and pancreatic neuroendocrine tumors, often resulting in the Alternative Lengthening of Telomeres (ALT) phenotype (Schwartzentruber et al., 2012; Jiao et al., 2011). Therapeutic strategies currently focus on exploiting the genomic instability caused by the loss of these chaperones, using synthetic lethal approaches with PARP, ATR, or WEE1 inhibitors (Teh et al., 2020; Liang et al., 2020). Additionally, experimental small molecule inhibitors targeting the interaction between H3.3 and its chaperones are being explored to disrupt oncogenic chromatin remodeling (Elsässer et al., 2012; Liu et al., 2012). Understanding the distinct roles of these complexes provides a framework for developing targeted epigenetic therapies in oncology and genetic disorders like ATRX syndrome (Gibbons et al., 1995).

Other names

HIRA complexDAXX/ATRX complexH3.3-specific chaperonesH3.3 deposition machineryHistone cell cycle regulator complexDEK

Inhibition of H3.3 deposition, induction of genomic instability, synthetic lethality in ATRX/DAXX-deficient cells, and disruption of chromatin stability.